FDA HQ in Silver Spring, Maryland (Credit: Ting Shen via Getty)
FDA lifts clinical hold on Audentes' gene therapy program after three patient deaths triggered alarms
The big prize of Astellas’ $3 billion gene therapy buyout last year is one step closer to getting back on track.
The FDA lifted its …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
